Annals of Surgical Oncology

, Volume 21, Supplement 4, pp 648–656

Elevated Expression of Girdin in the Nucleus Indicates Worse Prognosis for Patients with Estrogen Receptor-Positive Breast Cancer

  • Wen-Ting Peng
  • Xin Hu
  • Ling Yao
  • Yi-Zhou Jiang
  • Zhi-Ming Shao
Translational Research and Biomarkers

DOI: 10.1245/s10434-014-3746-y

Cite this article as:
Peng, WT., Hu, X., Yao, L. et al. Ann Surg Oncol (2014) 21(Suppl 4): 648. doi:10.1245/s10434-014-3746-y

Abstract

Background

Girdin was identified as a novel Akt substrate that contributes to a positive feedback loop between Girdin and Akt. Although several recent studies have demonstrated that Girdin is involved in tumor metastasis, the clinical implications of Girdin in breast cancer remain unclear.

Methods

To retrospectively evaluate the prognostic value of Girdin in breast cancer, we performed an immunohistochemistry screening for Girdin using tissue microarrays constructed from 250 patients who were histologically confirmed as having invasive ductal breast carcinoma at the Fudan University Shanghai Cancer Center.

Results

Our results demonstrated that the levels of Girdin in different subcellular distributions, including Girdin in the nucleus (GN) and the cytoplasm (GC) were each associated with the clinical parameters of breast cancer, including phospho-Akt (S473) [p = 0.014 for GN], phospho-Akt (T308) [p = 0.045 for GC], estrogen receptor (ER) [p = 0.012 for GN and p = 0.004 for GC], progesterone receptor (p = 0.028 for GC) and human epidermal growth factor receptor 2 status (p = 0.004 for GC). Moreover, we showed that elevated expression of GN indicated a worse disease-free survival (p = 0.032) and overall survival (p = 0.011) exclusively in the ER-positive breast cancer population.

Conclusions

Cumulatively, our findings suggest that GN might serve as an important prognostic factor for ER-positive breast carcinoma.

Supplementary material

10434_2014_3746_MOESM1_ESM.doc (94 kb)
Supplementary material 1 (DOC 94 kb)
10434_2014_3746_MOESM2_ESM.docx (3.6 mb)
Supplementary material 2 (DOCX 3658 kb)

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Wen-Ting Peng
    • 1
    • 2
    • 3
  • Xin Hu
    • 1
    • 3
  • Ling Yao
    • 1
    • 3
  • Yi-Zhou Jiang
    • 1
    • 2
    • 3
  • Zhi-Ming Shao
    • 1
    • 2
    • 3
  1. 1.Department of Breast Surgery, Shanghai Cancer Center and Cancer InstituteFudan UniversityShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Key Laboratory of Breast Cancer in ShanghaiFudan University Shanghai Cancer CenterShanghaiChina

Personalised recommendations